CYAD-101, an allogenic CAR-T designed to co-express an NKG2D-based CAR and an inhibitory peptide to interfere with TCR signaling, was tested in the alloSHRINK Phase I study for unresectable metastatic colorectal cancer. Here, KLRK1 is linked to metastatic colorectal cancer.